鼻咽癌调强放疗后长期生存结果及失败模式分析

doi:10.3760/cma.j.issn.1004-4221.2018.10.002

摘要
图/表
参考文献()
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要

目的回顾分析IMRT治疗鼻咽癌的10年生存结果及失败模式,为鼻咽癌的优化治疗提供参考。方法收集2001-2008年间865例采用IMRT的鼻咽癌患者的临床资料。生存分析采用Kaplan-Meier法,Logrank检验和单因素分析,Cox模型多因素预后分析。结果中位随访时间为132.0个月,全组患者10年无局部复发生存(LRFS)、无远处转移生存(DMFS)、无进展生存(PFS)、肿瘤特异生存(DSS)分别为92.0%、83.4%、75.7%、78.6%。共210例死亡,其中124例(124/210,59.0%)死于远处转移, 47例(41/210,22.3%)死于局部区域复发。DSS的独立不良预后因素包括年龄>50岁(P=0.00)、LDH≥245 IU/L (P=0.00)、Hb<120 g/L (P=0.01)、T2-T4期(P=0.00)、N1-N3期(P=0.00)和GTV-nx>20 cm³(P=0.00)。Ⅱ期鼻咽癌患者单纯放疗组与联合化疗组10年LRFS、DMFS、DSS均相近(P=0.83、0.22、0.23),Ⅲ期鼻咽癌患者联合化疗组10年LRFS、DSS均优于单纯放疗组(P=0.01、0.01)但10年DMFS相近(P=0.14),Ⅳ a+Ⅳ b期患者总体预后较差。结论 IMRT改善了鼻咽癌患者的远期生存,远处转移成为最主要的失败模式;而Ⅰ-Ⅱ期患者采用单纯IMRT可取得满意生存结果,联合化疗可进一步提高Ⅲ期患者LRFS及DSS,而Ⅳ a+Ⅳ b期患者治疗模式仍需更多探讨。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	田允铭
	韩非
	曾雷
	刘明珠
	白力
	钟小鹏
	蓝玉宏
	林承光
	黄劭敏
	邓小武
	赵充
	卢泰祥

关键词 ：鼻咽肿瘤/调强放射疗法, 失败模式, 预后

Abstract：

Objective To analyze the 10-year survival outcome and failure patterns for patients with nasopharyngeal carcinoma (NPC) after intensity-modulated radiotherapy (IMRT),aiming to provide reference for optimized treatment for NPC. Methods Clinical data of 866 patients with NPC receiving IMRT from January 2001 to December 2008 were retrospectively analyzed. Survival analysis was performed using the Kaplan-Meier estimator. Univariate analysis was carried out by log-rank test and multivariate analysis was performed using Cox proportional hazards model. Results The median follow-up time was 132 months. The 10-year local recurrence-free survival (LRFS),distant metastasis-free survival (DMFS),progression-free survival (PFS) and disease specific survival (DSS) were 92.0%,83.4%,75.7% and 78.6%,respectively. A total of 210 patients died including 124 patients (59.0%) from distant metastasis,which was the primary cause of death,and 47(22.3%) from local regional recurrence. Independent negative factors of DSS included age>50 years (P=0.00),LDH≥245 IU/L (P=0.00),Hb<120 g/L (P=0.01),T2-T4 staging (P=0.00),N1-N3 staging (P=0.00) and GTV-nx>20 cm³(P=0.00).The 10-year LRFS,DMFS and DSS of stage Ⅱ NPC patients did not significantly differ after IMRT alone and chemoradiotherapy (P=0.83,0.22,0.23).For patients with stage Ⅲ NPC,the 10-year LRFS and DSS in the chemoradiotherapy arm were significantly higher than those in the IMRT alone (P=0.01,0.01),whereas no statistical significance was observed in the DMFS between two groups (P=0.14).The overall survival of stage Ⅳ a+Ⅳ b NPC patients is relatively poor. Conclusions IMRT can improve the long-term survival of NPC patients. Distant metastasis is the primary failure pattern. Patients with stage Ⅰ-Ⅱ NPC can obtain satisfactory survival outcomes after IMRT alone. The addition of chemotherapy can further enhance the LRFS and DSS of stage Ⅲ NPC patients. However,the optimal therapeutic strategy remains to be urgently investigated for stage Ⅳ a+Ⅳ b NPC patients.

Key words： Nasopharyngeal neoplasms/intensity-modulated radiotherapy Failure pattern Prognosis

收稿日期: 2018-01-23

通讯作者: 韩非,Email: hanfei@sysucc.org.cn

引用本文:

田允铭,韩非,曾雷等. 鼻咽癌调强放疗后长期生存结果及失败模式分析[J]. 中华放射肿瘤学杂志, 2018, 27(10): 880-885.

Tian Yunming,Han Fei,Zeng Lei et al. Long-term survival outcome and failure pattern after intensity-modulated radiotherapy for nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2018, 27(10): 880-885.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2018.10.002 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2018/V27/I10/880

[1] Yu MC,Yuan JM.Epidemiology of nasopharyngeal carcinoma[J].Semin Cancer Biol,2002,12(6):421-429.
[2] Lee AW,Ng WT,Chan YH,et al. The battle against nasopharyngeal cancer[J].Radiother Oncol,2012,104(3):272278.DOI:10.1016/j.radonc.2012.08.001.
[3] Lee AW,Poon YF,Foo W,et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985:overall survival and patterns of failure[J].Int J Radiat Oncol Biol Phys,1992,23(2):261-270.
[4] Lee N,Xia P,Quivey JM,et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma:an update of the UCSF experience[J].Int J Radiat Oncol Biol Phys,2002,53(1):12-22.
[5] Kam MK,Teo PM,Chau RM,et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy:the Hong Kong experience[J].Int J Radiat Oncol Biol Phys,2004,60(5):1440-1450.DOI:10.1016/j.ijrobp.2004.05.022.
[6] Lin S,Pan J,Han L,Zhang X,et al.Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy:report on the 3-year outcome of a prospective series[J].Int J Radiat Oncol Biol Phys,2008,75(4),10711078.DOI:10.1016/j.ijrobp.2008.12.015.
[7] 赵充,肖巍魏,韩非,等.419例鼻咽癌调强放疗疗效和影响[J].中华放射肿瘤学杂志,2010,19(3):191-196. 10.3760/cma.j.issn.1004-4221.2010.03.005
Zhao C,Xiao WW,Han F,et al. Long-term outcome and prognostic factors of patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy[J].Chin J Radiat Oncol,2010,19(3):191-196.DOI:10.3760/cma.j.issn.1004-4221.2010.03.005.
[8] Ma J,Mai HQ,Hong MH,et al. Is the 1997 AJCC staging system for nasopharyngeal carcinoma prognostically useful for Chinese patient populations[J].Int J Radiat Oncol Biol Phys,2001,50(5):1181-1189.
[9] Mao YP,Liang SB,Liu LZ,et al. The N staging system in nasopharyngeal carcinoma with radiation therapy oncology group guidelines for lymph node levels based on magnetic resonance imaging[J].Clin Cancer Res,2008,14(22):7497-7503.DOI:10.1158/1078-0432.CCR-08-0271.
[10] Liu L,Liang S,Li L,et al. Prognostic impact of magnetic resonance imaging-detected cranial nerve involvement in nasopharyngeal carcinoma[J].Cancer,2009,115(9):1995-2003.DOI:10.1002/cncr.24201.
[11] 高劲,胡婧晔,夏云飞,等.血红蛋白持续下降是鼻咽癌放疗患者的不良预后因素[J].癌症,2010,29(5):561-566.
Gao J,Hu JY,Xia YF,et al. Continuous fall in hemoglobin level is a poor prognostic factor in patients with nasopharyngeal carcinoma treated with radiotherapy[J].Chin J Cancer,2010,29(5):561-566.
[12] Enis O,Murat G,Ferah Y,et al. Non-metastatic stage ⅠV nasopharyngeal carcinoma patients:analysis of the pattern of relapse and survival[J].Radiother Oncol,2004,72(1):71-77.
[13] Guo R,Sun Y,Yu XL,et al. Is primary tumor volume still a prognostic factor in intensity modulated radiation therapy for nasopharyngeal carcinoma.[J].Radiother Oncol,2012,104(3):294-299.DOI:10.1016/j.radonc.2012.09.001.
[14] Al-Sarraf M,Leblanc M,Giri PGS,et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasophagryngeal cancer:phase Ⅲ randomized intergroup study 0099[J].J Clin Oncol,1998,16:1310-1317.
[15] Wee J,Tan EH,Tai BC,et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with american joint committee on cancer/international union against cancer stage Ⅲ and Ⅳ nasopharyngeal cancer of the endemic variety[J].J Clin Oncol.2005,23(27):6730-6738.
[16] Chen QY,Wen YP,Mai HQ,et al. Concurrent chemoradiotherapy vs. radiotherapy alone in stage Ⅱ nasopharyngeal carcinoma:phase Ⅲ randomized trial[J].J Natl Cancer Inst,2011,103(23):1761-70.DOI:10.1093/jnci/djr432.
[17] Tham IW,Lin SJ,Pan JJ,et al. Intensity-modulated radiation therapy without concurrent chemotherapy for stage iib nasopharyngeal cancer[J].Ame J Clin Oncol,2010,33(2):294-299.DOI:10.1097/COC.0b013e3181 d2edab.
[18] Xu C,Zhang L,Chen Y,et al. Chemoradiotherapy versus radiotherapy alone in stage Ⅱ nasopharyngeal carcinoma:A systemic review and meta-analysis of 2138 patients[J].J Cancer,8(2),287-297.DOI:10.7150/jca.17317.